See more : Fraser and Neave, Limited (FNEVF) Income Statement Analysis – Financial Results
Complete financial analysis of Catalyst Pharmaceuticals, Inc. (CPRX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Catalyst Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Signpost India Limited (SIGNPOST.NS) Income Statement Analysis – Financial Results
- New Relic, Inc. (0K79.L) Income Statement Analysis – Financial Results
- DCM Financial Services Limited (DCMFINSERV.BO) Income Statement Analysis – Financial Results
- Sound Financial Bancorp, Inc. (SFBC) Income Statement Analysis – Financial Results
- Australian Ethical Investment Ltd. (AEF.AX) Income Statement Analysis – Financial Results
Catalyst Pharmaceuticals, Inc. (CPRX)
About Catalyst Pharmaceuticals, Inc.
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company also develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3, as well as to treat hereditary neuropathy with liability to pressure palsies. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 398.20M | 214.20M | 140.83M | 119.07M | 102.31M | 500.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 488.96K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 84.53M | 34.39M | 21.88M | 17.04M | 14.76M | 19.92M | 45.69K | 43.41K | 34.47K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 313.67M | 179.81M | 118.95M | 102.03M | 87.55M | -19.42M | -45.69K | -43.41K | -34.47K | 0.00 | 0.00 | 0.00 | 0.00 | 488.96K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 78.77% | 83.94% | 84.46% | 85.69% | 85.57% | -3,883.84% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 93.15M | 19.79M | 16.94M | 16.50M | 18.84M | 19.92M | 11.38M | 11.37M | 11.80M | 10.12M | 8.10M | 2.66M | 3.38M | 2.31M | 5.10M | 8.71M | 2.99M | 989.14K | 1.46M | 378.25K | 0.00 | 137.68K |
| General & Administrative | 47.02M | 28.71M | 23.48M | 20.67M | 33.58M | 15.88M | 7.30M | 7.91M | 8.60M | 4.47M | 2.21M | 2.56M | 2.70M | 2.21M | 2.18M | 2.18M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 86.69M | 29.47M | 26.15M | 23.57M | 3.30M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 133.71M | 58.18M | 49.63M | 44.23M | 36.88M | 15.88M | 7.30M | 7.91M | 8.60M | 4.47M | 2.21M | 2.56M | 2.70M | 2.21M | 2.18M | 2.18M | 2.04M | 1.91M | 359.28K | 164.70K | 0.00 | 0.00 |
| Other Expenses | 0.00 | 2.88M | 282.00K | 586.90K | 1.59M | 1.29M | 454.16K | 321.61K | 100.39K | 76.23K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -428.62K | 118.27K |
| Operating Expenses | 259.43M | 77.97M | 66.56M | 60.73M | 55.72M | 35.80M | 18.68M | 19.28M | 20.40M | 14.59M | 10.31M | 5.22M | 6.08M | 4.51M | 7.28M | 10.89M | 5.03M | 2.90M | 1.82M | 542.96K | -428.62K | 255.95K |
| Cost & Expenses | 311.39M | 112.37M | 88.45M | 77.77M | 70.48M | 35.80M | 18.68M | 19.28M | 20.40M | 14.59M | 10.31M | 5.22M | 6.08M | 4.51M | 7.28M | 10.89M | 5.03M | 2.90M | 1.82M | 542.96K | -428.62K | 255.95K |
| Interest Income | 0.00 | 0.00 | 282.00K | 587.00K | 1.59M | 1.29M | 454.16K | 321.61K | 100.39K | 76.23K | 47.42K | 14.98K | 10.99K | 17.86K | 33.47K | 329.35K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.29M | 454.16K | 321.61K | 100.39K | 76.23K | 47.42K | 14.98K | 10.99K | 17.86K | 33.47K | 329.35K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 32.88M | 1.49M | 484.00K | 885.32K | 297.73K | 37.98K | 45.69K | 43.41K | 34.47K | 26.57K | 22.48K | 10.89K | 42.84K | 25.74K | 30.23K | 32.76K | 15.76K | 4.93K | 1.37K | 366.00 | 0.00 | 0.00 |
| EBITDA | 119.69M | 101.84M | 52.39M | 41.30M | 31.82M | -35.26M | -18.49M | -18.03M | -20.46M | -13.57M | -8.40M | -6.35M | -6.35M | -4.00M | -7.21M | -10.53M | -5.01M | -2.72M | -1.82M | -542.59K | -428.62K | -255.95K |
| EBITDA Ratio | 30.06% | 47.54% | 37.20% | 34.69% | 31.11% | -7,059.03% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -817.75% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | 86.81M | 101.84M | 52.39M | 41.30M | 31.82M | -35.30M | -18.68M | -19.28M | -20.40M | -14.59M | -10.31M | -5.22M | -6.08M | -4.02M | -7.28M | -10.89M | -5.03M | -2.90M | -1.82M | -542.96K | -428.62K | -255.95K |
| Operating Income Ratio | 21.80% | 47.54% | 37.20% | 34.69% | 31.11% | -7,059.03% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -823.01% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 7.70M | 2.88M | 282.00K | 586.90K | 1.59M | 1.29M | 267.26K | 1.21M | 165.39K | -917.63K | -1.84M | 1.14M | -308.92K | 17.86K | 33.47K | 329.35K | 887.64K | 172.87K | 16.79K | 3.14K | 0.00 | 0.00 |
| Income Before Tax | 94.51M | 104.72M | 52.67M | 41.89M | 33.41M | -34.00M | -18.41M | -18.07M | -20.23M | -15.51M | -12.15M | -4.08M | -6.39M | -4.01M | -7.24M | -10.56M | -4.14M | -2.73M | -1.81M | -539.82K | 0.00 | -255.95K |
| Income Before Tax Ratio | 23.73% | 48.89% | 37.40% | 35.18% | 32.66% | -6,800.70% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -819.36% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 23.10M | 21.64M | 13.19M | -33.09M | 1.53M | 2.58M | 141.22K | -929.54K | -99.47K | 993.87K | 1.84M | -1.16M | 308.92K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 428.62K | 0.00 |
| Net Income | 71.41M | 83.08M | 39.48M | 74.98M | 31.88M | -34.00M | -18.41M | -18.07M | -20.23M | -15.51M | -12.15M | -4.08M | -6.39M | -4.01M | -7.24M | -10.56M | -4.14M | -2.73M | -1.81M | -539.82K | -428.62K | -255.95K |
| Net Income Ratio | 17.93% | 38.79% | 28.03% | 62.97% | 31.16% | -6,800.70% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -819.36% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | 0.67 | 0.80 | 0.38 | 0.72 | 0.31 | -0.33 | -0.21 | -0.22 | -0.25 | -0.24 | -0.27 | -0.14 | -0.29 | -0.22 | -0.48 | -0.81 | -0.33 | -0.36 | -0.29 | -0.18 | -0.15 | -0.11 |
| EPS Diluted | 0.63 | 0.75 | 0.37 | 0.71 | 0.30 | -0.33 | -0.21 | -0.22 | -0.25 | -0.24 | -0.27 | -0.14 | -0.29 | -0.22 | -0.48 | -0.81 | -0.33 | -0.36 | -0.29 | -0.18 | -0.15 | -0.11 |
| Weighted Avg Shares Out | 106.28M | 103.37M | 103.38M | 103.51M | 102.94M | 102.63M | 85.80M | 82.88M | 80.86M | 64.14M | 45.45M | 30.03M | 21.73M | 18.58M | 15.07M | 13.01M | 12.53M | 7.69M | 6.20M | 2.92M | 2.92M | 2.36M |
| Weighted Avg Shares Out (Dil) | 113.75M | 111.38M | 107.80M | 106.24M | 106.02M | 102.63M | 85.80M | 82.88M | 80.86M | 64.14M | 45.45M | 30.03M | 21.73M | 18.58M | 15.07M | 13.01M | 12.53M | 7.69M | 6.20M | 2.92M | 2.92M | 2.36M |
Wall Street Analysts See a 56.65% Upside in Catalyst (CPRX): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 56.7% in Catalyst (CPRX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an...
Recent Price Trend in Catalyst (CPRX) is Your Friend, Here's Why
If you are looking for stocks that are well positioned to maintain their recent uptrend, Catalyst (CPRX) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Top 3 Health Care Stocks That May Crash In August
As of Aug 14, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Catalyst Pharmaceuticals, Inc. (CPRX) Q2 2024 Earnings Call Transcript
Call End: Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX ) Q2 2024 Earnings Conference Call August 08, 2024, 08:30 AM ET Company Participants Michael Kalb - Chief Financial Officer Richard Daly - President and Chief Executive Officer Jeffrey Del Carmen - Chief Commercial...
Catalyst (CPRX) Rises as Q2 Earnings & Revenues Beat Estimates
Catalyst (CPRX) gains as it reports strong second-quarter results, wherein earnings and revenues beat the Zacks Consensus Estimate, primarily driven by strong Firdapse sales.
Catalyst (CPRX) Reports Q2 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for Catalyst (CPRX) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates...
Catalyst Pharmaceutical (CPRX) Beats Q2 Earnings and Revenue Estimates
Catalyst Pharmaceutical (CPRX) came out with quarterly earnings of $0.56 per share, beating the Zacks Consensus Estimate of $0.42 per share. This compares to earnings of $0.33 per share a year ago.
Catalyst Pharmaceuticals Reports Strong Second Quarter 2024 Financial Results and Provides Corporate Update
Delivered Robust Revenue Performance, Fueled by Exceptional Commercial Execution and Early Success of the U.S. AGAMREE® Product Launch
Catalyst Pharmaceuticals Enters Into an Exclusive License, Supply and Commercialization Agreement with Kye Pharmaceuticals for AGAMREE® in Canada
CORAL GABLES, Fla., July 24, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that it...
Catalyst Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 7, 2024
The Company will Host a Conference Call and Webcast on Thursday, August 8, 2024, at 8:30 AM ET The Company will Host a Conference Call and Webcast on Thursday, August 8, 2024, at 8:30 AM ET
Source: https://incomestatements.info
Category: Stock Reports